Rapid, non-destructive, cell-based screening assays for agents that modulate growth, death, and androgen receptor activation in prostate cancer cells

Prostate

Volumn 67, Issue 4, 2007, Pages 416-426

  Tavassoli, Peyman ^a,b   Snoek, Rob ^b   Ray, Mira ^c   Rao, Leticia Gomez ^d   Rennie, Paul S ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Apoptosis; Dichlorvos; EGFP; IL 6; Lentivirus; Osteoblast conditioned media

Indexed keywords

ANDROGEN RECEPTOR; DICHLORVOS; ENHANCED GREEN FLUORESCENT PROTEIN; FORSKOLIN; INTERLEUKIN 6; METRIBOLONE; MITOXANTRONE; PESTICIDE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CULTURE MEDIUM; EMBRYO; HUMAN; HUMAN CELL; LENTIVIRINAE; MALE; OSTEOBLAST; PRIORITY JOURNAL; PROSTATE CANCER; VIRUS INFECTION;

ADENOCARCINOMA; APOPTOSIS; ARYL HYDROCARBON HYDROXYLASES; CELL CULTURE TECHNIQUES; CELL DIVISION; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; DICHLORVOS; FORSKOLIN; GREEN FLUORESCENT PROTEINS; HUMANS; INSECTICIDES; INTERLEUKIN-6; MALE; OSTEOBLASTS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STEROID HYDROXYLASES;

EID: 33847382319     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20532     Document Type: Article

References (49)

1. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;2(25):276-300.
2. Culig Z, Klocker H, Bartsch G, Steiner H, Hobisch A. Androgen receptors in prostate cancer. J Urol 2003;170(4 Pt 1):1363-1369.
3. Setlur SR, Rubin MA. Current thoughts on the role of the androgen receptor and prostate cancer progression. Adv Anat Pathol 2005;12(5):265-270.
4. Gioeli D. Signal transduction in prostate cancer progression. Clin Sci (Lond) 2005;108(4):293-308.
5. Blaszczyk N, Masri BA, Mawji NR, Ueda T, McAlinden G, Duncan CP, Bruchovsky N, Schweikert HU, Schnabel D, Jones EC, Sadar MD. Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin Cancer Res 2004;10(5):1860-1869.
6. Culig Z, Steiner H, Bartsch G, Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005;95(3):497-505.
7. Degeorges A, Tatoud R, Fauvel-Lafeve F, Podgorniak MP, Millot G, de Cremoux P, Calvo F. Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int J Cancer 1996;68(2):207-214.
8. Lu Y, Zhang J, Dai J, Dehne LA, Mizokami A, Yao Z, Keller ET. Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin Exp Metastasis 2004;21(5):399-408.
9. Wang MH, Abreu-Delgado Y, Young CY. Effects of vitamin C on androgen receptor mediated actions in human prostate adenocarcinoma cell line LAPC-4. Urology 2003;62(1):167-171.
10. Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, Tokizane T, Fukui T, Ono Y, Inoue H, Shin M, Tsujimoto Y, Takayama H, Aozasa K, Okuyama A. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 2001;93(22):1739-1746.
11. Ueda T, Mawji NR, Bruchovsky N, Sadar MD. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 2002;277(41):38087-38094.
12. Darbre P. Preface. Best Pract Res Clin Endocrinol Metab 2006;20(1):vii-x.
13. Kim HJ, Park YI, Dong MS. Effects of 2,4-D and DCP on the DHT-induced androgenic action in human prostate cancer cells. Toxicol Sci 2005;88(1):52-59.
14. Kavlock R, Cummings A. Mode of action: Inhibition of androgen receptor function-vinclozolin-induced malformations in reproductive development. Crit Rev Toxicol 2005;35(8-9):721-726.
15. Sonnenschein C, Soto AM. An updated review of environmental estrogen and androgen mimics and antagonists. J Steroid Biochem Mol Biol 1998;65(1-6):143- 150.
16. Wetherill YB, Fisher NL, Staubach A, Danielsen M, de Vere White RW, Knudsen KE. Xenoestrogen action in prostate cancer: Pleiotropic effects dependent on androgen receptor status. Cancer Res 2005;65(1):54-65.
17. Handelsman DJ. Designer androgens in sport: When too much is never enough. Sci STKE 2004;2004(244):pe41.
18. Thevis M, Kamber M, Schanzer W. Screening for metabolically stable aryl-propionamide-derived selective androgen receptor modulators for doping control purposes. Rapid Commun Mass Spectrom 2006;20(5):870-876.
19. Casner PR. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006;354(18):1950-1951; author reply 1950-1951.
20. Jiang C, Lee HJ, Li GX, Guo J, Malewicz B, Zhao Y, Lee EO, Lee JH, Kim MS, Kim SH, Lu J. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: Identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Cancer Res 2006;66(1):453-463.
21. Michelini E, Magliulo M, Leskinen P, Virta M, Karp M, Roda A. Recombinant cell-based bioluminescence assay for androgen bioactivity determination in clinical samples. Clin Chem 2005;51(10):1995-1998.
22. Ho SM, Tang WY, Belmonte de Frausto J, Prins GS. Developmental exposure to estradiol and bisphenol a increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res 2006;66(11):5624-5632.
23. Sonneveld E, Jansen HJ, Riteco JA, Brouwer A, van der Burg B. Development of androgen- and estrogen-responsive bioassays, members of a panel of human cell line-based highly selective steroid-responsive bioassays. Toxicol Sci 2005;83(1):136-148.
24. Araki N, Ohno K, Takeyoshi M, Iida M. Evaluation of a rapid in vitro androgen receptor transcriptional activation assay using AR-EcoScreen cells. Toxicol In Vitro 2005;19(3):335-352.
25. Rao LG, Kung Sutherland MS, Muzaffar SA, Wylie JN, McBroom RJ, Murray TM. Positive interaction between 17 beta-Estradiol and parathyroid hormone in normal human osteoblasts cultured long term in the presence of dexamethasone. Osteoporos Int 1996;6(2):111-119.
26. Rao LG, Liu LJ, Murray TM, McDermott E, Zhang X. Estrogen added intermittently, but not continuously, stimulates differentiation and bone formation in SaOS-2 cells. Biol Pharm Bull 2003;26(7):936-945.
27. Yu D, Jia WW, Gleave ME, Nelson CC, Rennie PS. Prostate-tumor targeting of gene expression by lentiviral vectors containing elements of the probasin promoter. Prostate 2004;59(4):370-382.
28. Zhang J, Thomas TZ, Kasper S, Matusik RJ. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 2000;141(12):4698-4710.
29. Di Lorenzo G, De Placido S. Hormone refractory prostate cancer (HRPC): Present and future approaches of therapy. Int J Immunopathol Pharmacol 2006;19(1):11-34.
30. Miyake H, Hara S, Arakawa S, Kamidono S, Hara I. Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model. Br J Cancer 2001;84(6):859-863.
31. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350(16):1655-1664.
32. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999;39(4):246-261.
33. Zhau HE, Li CL, Chung LW. Establishment of human prostate carcinoma skeletal metastasis models. Cancer 2000;88(12 Suppl):2995-3001.
34. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991;51(14):3753-3761.
35. Chiao JW, Moonga BS, Yang YM, Kancherla R, Mittelman A, Wu-Wong JR, Ahmed T. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 2000;83(3):360-365.
36. Fu Z, Dozmorov IM, Keller ET. Osteoblasts produce soluble factors that induce a gene expression pattern in non-metastatic prostate cancer cells, similar to that found in bone metastatic prostate cancer cells. Prostate 2002;51(1):10-20.
37. Cillo JE Jr, Gassner R, Koepsel RR, Buckley MJ. Growth factor and cytokine gene expression in mechanically strained human osteoblast-like cells: Implications for distraction osteogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90(2):147-154.
38. Wang C, Duan Y, Markovic B, Barbara J, Howlett CR, Zhang X, Zreiqat H. Phenotypic expression of bone-related genes in osteoblasts grown on calcium phosphate ceramics with different phase compositions. Biomaterials 2004;25(13):2507-2514.
39. Spyrou P, Papaioannou S, Hampson G, Brady K, Palmer RM, McDonald F. Cytokine release by osteoblast-like cells cultured on implant discs of varying alloy compositions. Clin Oral Implants Res 2002;13(6):623-630.
40. Furr BJ, Valcaccia B, Curry B, Woodburn JR, Chesterson G, Tucker H. ICI 176,334: A novel non-steroidal, peripherally selective antiandrogen. J Endocrinol 1987;113(3):R7-R9.
41. Nazareth LV, Weigel NL. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 1996;271(33):19900-19907.
42. Jia L, Choong CS, Ricciardelli C, Kim J, Tilley WD, Coetzee GA. Androgen receptor signaling: Mechanism of interleukin-6 inhibition. Cancer Res 2004;64(7):2619-2626.
43. Kim J, Jia L, Stallcup MR, Coetzee GA. The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus. J Mol Endocrinol 2005;34(1):107-118.
44. Sadar MD. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 1999;274(12):7777-7783.
45. Van Maele-Fabry G, Laurent C, Willems JL. Dichlorvos and carcinogenicity: A systematic approach to a regulatory decision. Regul Toxicol Pharmacol 2000;31(1):13-21.
46. Andersen HR, Vinggaard AM, Rasmussen TH, Gjermandsen IM, Bonefeld-Jorgensen EC. Effects of currently used pesticides in assays for estrogenicity, androgenicity, and aromatase activity in vitro. Toxicol Appl Pharmacol 2002;179(1):1-12.
47. Liu QY, Rubin MA, Omene C, Lederman S, Stein CA. Fas ligand is constitutively secreted by prostate cancer cells in vitro. Clin Cancer Res 1998;4(7):1803-1811.
48. Ghanadian R, Auf G, Smith CB, Chisholm GD, Blacklock NJ. Androgen receptors in the prostate of the Rhesus monkey. Urol Res 1977;5(4):169-173.
49. Fedoruk MN. (Ph.D. thesis) The modulation of androgen action in prostate cancer by exogenous chemicals, Efflux Transporter P-glycoprotein and Y-Box Binding Protein-1, University of British Columbia, 2006, pp 89-126.